TOPIC

Progress in the Treatment of Poor Prognosis GI Malignancies: Pancreatic, Biliary Tract and Peritoneal Malignancies

MODERATORS

Hope Rugo, MD, Professor of Medicine, Director of Breast Oncology and Clinical Trials Education, Medical Director of Cancer Infusion Services, UCSF Helen DIller Family Comprehensive Cancer Center

Laura Crocitto, MD, Vice President and Chief Medical Officer for Cancer Services, Medical Director, UCSF Helen Diller Family Comprehensive Cancer Center

-------

PRESENTATIONS

"Pancreatic Cancer in 2024: Are we Finally Moving Beyond Just Chemotherapy?"

Andrew Ko, MD, FASCO, Professor of Medicine, Associate Chief, Division of Hematology/Oncology, UCSF Helen Diller Family Comprehensive Cancer Center

Upon completion of this course, participants will have improved their skills and strategies for:

• Reviewing the latest data regarding the optimal selection of chemotherapy for patients with metastatic pancreatic cancer.
• Understanding how molecular findings can inform the use of targeted and/or immune-based therapies for patients with metastatic pancreatic cancer, both in standard practice and in clinical trial settings.

-------

"The Role of Cytoreductive Surgery and HIPEC for Peritoneal Malignancies"

Mohamed Adam, MD, Assistant Professor in Residence, Division of Surgical Oncology, UCSF

Upon completion of this course, participants will have improved their skills and strategies for:

• Understanding the rationale, indications and patient selection criteria
• Navigating the surgical techniques and multidisciplinary collaboration

-------

"Updates in Advanced Biliary Tract Cancers: Expanding Roles for Immunotherapy and Targeted Therapies"

Robin K. ("Katie") Kelley, MD, Professor of Medicine, Co-Director of Clinical Research, Division of Hematology/Oncology; Chair, Data and Safety Monitoring Committee, UCSF Helen DIller Family Comprehensive Cancer Center

Upon completion of this course, participants will have improved their skills and strategies for:

• Educating providers on the improvement in outcomes with addition of immune checkpoint inhibition to standard chemotherapy as first-line therapy for biliary tract cancers
• Increasing awareness of expanding options for targeted therapies in molecularly-defined subsets of biliary tract cancers

-------

REGISTRATION

To secure your spot, please register in advance. 

• REGISTER WITH CME
• REGISTER WITHOUT CME